• Users Online: 253
  • Print this page
  • Email this page
Year : 2018  |  Volume : 1  |  Issue : 1  |  Page : 43-45

Response to osimertinib in EGF816-resistant T790M-mutated lung cancer

Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada

Correspondence Address:
Dr. James C Kuo
Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jco.jco_3_18

Rights and Permissions

A 75-year-old male with metastatic adenocarcinoma of the lung that harbored an epidermal growth factor receptor (EGFR) mutation had disease control for 16 months with EGF816, an investigational, third-generation EGFR tyrosine kinase inhibitor (TKI), in a phase I clinical trial. On disease progression, his treatment was switched to an earlier third-generation EGFR TKI, osimertinib. A rapid response occurred but was short-lived for only 10 weeks, before a rapid progression ensued. The mechanism of sequential resistance to EGF816, and subsequently, osimertinib in this male was indeterminant because of the absence of baseline genomic profiling of the tumor. Repeated molecular profiling demonstrated persistent EGFR mutations and a possibly emergent TP53 G266E mutation. This case highlighted the importance of serial biopsies for genomic analysis to understand emergent TKI resistance. As non-cross resistance may be present among the various EGFR TKI, the potential in the sequential approach in targeted therapy should be explored.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded341    
    Comments [Add]    

Recommend this journal